abstract |
The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti- BCMA (B cell maturation antigen) antibody, Belantamab mafodotin - GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat - PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor. |